

## **LIST OF PEER REVIEWED PUBLICATIONS**

---

**Original articles**

1. Bogner E-M, Daly AF, Gulde S, Karhu A, Irmeler M, Beckers J, Mohr H, Beckers A, **Pellegata NS**. (2020) miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance. *Int J Cancer*. doi: 10.1002/ijc.33268.
2. Glantschnig C, Mattijssen F, Vogl ES, Ali Khan A, Rios Garcia M, Fischer K, Müller T, Uhlenhaut H, Nawroth P, Scheideler M, Rose AJ, **Pellegata N**, Herzig S. (2019) The glucocorticoid receptor in brown adipocytes is dispensable for the systemic control of energy homeostasis through brown adipose tissue. *EMBO Rep*. 20:e48552.
3. Daly A, Rostomyan L, Betea D, Bonneville JF, Villa C, **Pellegata NS**, Waser B, Reubi JC, Waeber Stephan C, Christ E, Beckers A. (2019) AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. *Endocr Connect*. 8: 367-377.
4. Idrizaj E, Garella R, Castellini G, Mohr H, **Pellegata NS**, Francini F, Ricca V, Squecco R, Baccari MC. (2018) Adiponectin affects the mechanical responses in strips from the mouse gastric fundus. *World J Gastroenterol* 24:4028-4035.
5. Molatore S, Kügler A, Irmeler M, Wiedemann T, Neff F, Feuchtinger A, Beckers J, Robledo M, Roncaroli F, **Pellegata NS**. (2018) Characterization of neuroendocrine tumors in heterozygous mutant MENX rats: a novel model of invasive medullary thyroid carcinoma. *Endocr Relat Cancer* 25:145-162.
6. Lee M, Minaskan N, Wiedemann T, Irmeler M, Beckers J, Yousefi BH, Kaissis G, Braren R, Laitinen I, **Pellegata NS**. (2017) The norepinephrine transporter as a putative predictive biomarker for PI3K/mTOR inhibition in pheochromocytoma. *Endocr Relat Cancer* 24:1-15.
7. Borsari S, Pardi E, **Pellegata NS**, Lee M, Saponaro F, Torregrossa L, Basolo F, Paltrinieri E, Zatelli MC, Materazzi G, Miccoli P, Marcocci C, Cetani F. (2017) Loss of p27 expression correlates with MEN1 gene mutations in sporadic parathyroid adenomas. *Endocrine* 55:386-397.
8. Rohm M, Schäfer M, Laurent V, Üstünel BE, Niopek K, Algire C, Hautzinger O, Sijmonsma TP, Zota A, Medrikova D, **Pellegata NS**, Ryden M, Kulyte A, Dahlman I, Arner P, Petrovic N, Cannon B, Amri EZ, Kemp BE, Steinberg GR, Janovska P, Kopecky J, Wolfrum C, Blüher M, Berriel Diaz M, Herzig S. (2016) An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice. *Nature Medicine* 22:1120-1130.
9. Wang Y, Li W, Phay JE, Shen R, **Pellegata N**, Saji M, Ringel MD, de la Chapelle A and He H. (2016) Primary cell culture systems for human thyroid studies. *Thyroid*, 26:1131-40.
10. Wiedemann T, Peitzsch M, Qin N, Neff F, Ehrhart-Bornstein M, Eisenhofer G, **Pellegata NS**. (2016) Morphology, biochemistry and pathophysiology of MENX-related pheochromocytoma recapitulate the clinical features. *Endocrinology* 157:3157-66.
11. Naves LA, Daly AF, Dias LA, Yuan B, Oliveira Zakir JC, Barcellos Barra G, Palmeira L, Villa C, Trivellin G, Jreige A Jr, Cavalcante Neto FF, Liu P, **Pellegata NS**, Stratakis CA, Lupski JR, Beckers A. (2016) Aggressive tumor growth and clinical evolution in a patient with X-linked acrogigantism syndrome. *Endocrine* 51: 236-44.
12. Wiedemann T, Bielohuby M, Müller TD, Bidlingmaier M, **Pellegata NS**. (2016) Obesity in MENX rats is accompanied by high circulating levels of ghrelin and improved insulin sensitivity. *Diabetes* 65:406-20.
13. Leinhäuser I, Richter A, Lee M, Höfig I, Anastasov N, Fend F, Ercolino T, Mannelli M, Gimenez-Roqueplo AP, Robledo M, de Krijger R, Felix Beuschlein F, Michael J, Atkinson MJ, **Pellegata NS**. (2015) Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. *OncoTarget* 6:39111-26.
14. Hrabě de Angelis M, .... **Pellegata NS**, ...Brown S. (2015) Deciphering mammalian gene function through broad based phenotypic screens across a consortium of mouse clinics. *Nature Genetics* 47:969-78.
15. van Berkel A, Rao JU, Lenders JWM, **Pellegata NS**, Kusters B, Piscaer I, Hermus ARMM, Plantinga TS, Langenhuijsen JF, Vriens D, Janssen MJR, Gotthardt M and Timmers HJLM. (2015)

- Semi-quantitative <sup>123</sup>I-metaiodobenzylguanidine scintigraphy to distinguish pheochromocytoma from physiological adrenal uptake and its correlation with genotype-dependent expression of catecholamine transporters. *J Nucl Med* 56:839-46.
16. Lee M, Wiedemann T, Gross C, Roncaroli F, Braren R, **Pellegata NS**. (2015) Targeting PI3K/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas. *Clinical Cancer Research* 21:3204-3215.
  17. Beckers A, Lodish MB, Trivellin G, Rostomyan L, Lee M, Faucz FR, Yuan B, Choong CS, JCaberg J-H, Verrua E, Naves LA, Cheetham TD, Young J, Lysy PA, Petrossians P, Cotterill A, Shah NS, Metzger D, Castermans E, Ambrosio MR, Villa C, Strebkova N, Mazerkina N, Gaillard S, Barra GB, Casulari LA, Neggers SJ, Salvatori R, Jaffrain-Rea M-L, Zacharin M, Santamaria BL, Zacharieva S, Lim EM, Mantovani G, Zatelli MC, T Collins MT, Bonneville J-F, Quezado M, Chittiboina P, Oldfield EH, Bours V, Liu P, De Herder W, **Pellegata NS**, Lupski JR, Daly AF and Stratakis CA. (2015) X-linked Acrogigantism (X-LAG) Syndrome: Clinical Profile and Therapeutic Responses. *Endocrine Related Cancer* 22:353-67.
  18. Wester HJ, Keller U, Beer AJ, Schottelius M, Philipp-Abbrederis K, Hoffmann F, Šimeček J, **Pellegata NS**, Rudelius M, Kessler H, Schwaiger M. (2015) Disclosing the CXCR4 receptor expression in lymphoproliferative diseases by targeted molecular imaging. *Theranostics* 5: 618-630.
  19. Sambugaro S, Di Ruvo M, Ambrosio MR, Tagliati F, **Pellegata NS**, degli Uberti E, Zatelli MC. (2015) Early onset acromegaly associated with a new CDKN1B promoter deletion. *Endocrine* 49:58-64.
  20. Pardi E, Mariotti S, **Pellegata NS**, Benfini K, Borsari S, Saponaro F, Torregrossa L, Cappai A, Satta C, Mastinu M, Marcocci C, Cetani F. (2015) Functional characterization of a CDKN1B mutation in a Sardinian kindred with 2 multiple endocrine neoplasia type 4 (MEN4). *Endocr Connect.* 4:1-8.
  21. Miras AD, Mogford J, Wright J, Mendoza NN, Xekouki P, Lakhani A, **Pellegata NS**, Stratakis C, Roncaroli F and Russell-Jones D. (2015) Ovarian hyperstimulation from ectopic FSH hypersecretion. *The Lancet* 385:392.
  22. Vukicevic V, Fernandez Rubin de Celis M, **Pellegata NS**, Bornstein SR, Androutsellis-Theotokis and A Ehrhart-Bornstein M. (2015) Adrenomedullary Progenitor Cells: Isolation and Characterization of a Highly Potent Stem Cell Population. *Mol. Cell. Endocrinol* 408:178-184.
  23. Chin SO, Hwang JK, Rhee SY, Chon S, Oh S, Lee M, **Pellegata NS**, Kim SW. (2015) Acromegaly due to a Macroinvasive Plurihormonal Pituitary Adenoma and a Rectal Carcinoid Tumor. *Endocrinol Metab (Seoul)* 30:389-94.
  24. Lee M, Lupp A, Mendoza N, Martin N, Beschorner R, Honegger J, Schlegel J, Shively T, Pulz E, Schulz S, Roncaroli F, **Pellegata NS**. (2014) Somatostatin receptor 3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. *Endocr Relat Cancer* 22:111-9.
  25. Longuini VC, Lourenco DM, Sekiya T, Meirelles O, Goncalves TD, Coutinho FL, Francisco G, Osaki LH, Chammas R, Alves VAF, Siqueira SAC, Schlesinger D, Naslavsky MS, Zatz M, Duarte YAO, Lebrão ML, Gama P, Lee M, Molatore S, Pereira MAA, Jallad RS, Bronstein MD, Cunha-Neto MB, Liberman B, Fragoso MCBV, Toledo SPA, **Pellegata NS**, Toledo RA. (2014) Association between the p27 rs2066827 variant and tumor multiplicity in patients harboring MEN1 germline mutations. *European J Endocrinol* 171:335-42.
  26. Sekiya T, Bronstein MD, Benfini K, Longuini VC, Jallad RS, Machado MC, Goncalves TD, Osaki LH, Higashi L, Viana J Jr, Kater C, Lee M, Molatore S, Francisco G, Chammas R, Naslavsky MS, Schlesinger D, Gama P, Duarte YAO, Lebrão ML, Zatz M, Meirelles O, Liberman B, Fragoso MCBV, Toledo SPA, **Pellegata NS**, Toledo RA. (2014) p27 variant and corticotropinoma susceptibility: a genetic and in vitro study. *Endocr Relat Cancer* 21:395-404.
  27. Gaertner FC, Wiedemann T, Yousefi BH, Lee M, Repokis I, Higuchi T, Nekolla SG, Yu M, Robinson S, Schwaiger M, **Pellegata NS**. (2013) Preclinical evaluation of [<sup>18</sup>F]LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model. *J Nucl Med* 54:2111-7.
  28. Lee M, Marinoni I, Irmeler I, Psaras T, Honegger JB, Beschorner R, Anastasov N, Beckers J,

- Theodoropoulou M, Roncaroli F, **Pellegata NS**. (2013) Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas. *Acta Neuropathol* 126:137-50.
29. Lee M, **Pellegata NS**. (2013) Folate receptor-mediated drug targeting: a possible strategy for nonfunctioning pituitary adenomas? *Endocrinology* 154:1387-9.
30. Occhi G, Regazzo D, Trivellin G, Boaretto F, Ciato D, Bobisse S, Ferasin S, Cetani F, Pardi E, Korbonits M, **Pellegata NS**, Sidarovich V, Quattrone A, Opocher G, Mantero F, Scaroni C. (2013) A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes MEN4 Phenotype. *PLOS Genetics* 9:e1003350.
31. Marinoni I, Lee M, Mountford S, Perren A, Bravi I, Jennen L, Feuchtinger A, Roncaroli F, **Pellegata NS**. Characterization of MENX-associated pituitary tumors. (2013) *Neuropath App Neurobiol* 39:256-69.
32. Tichomirowa MA, Lee M, Barlier A, Daly AF, Marinoni I, Jaffrain-Rea M-L, Theodoropoulou M, Rodien P, Naves LA, Rohmer V, Estour B, Lecomte P, Borson-Chazot F, Penfornis A, Yaneva M, Guitelman M, Casterman E, Verhaege C, Wémeau J-L, Tabarin A, Caron P, Fajardo Montañana C, Delemer B, Archambeaud F, Zacharieva S, Brue T, Enjalbert A, Bours V, **Pellegata NS**, Beckers A. Cyclin dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenomas (FIPA) kindreds. (2012) *Endocr Rel Cancer*, 19:233-41.
33. Waser B, Beetschen K, **Pellegata NS**, Reubi JC. (2011) Incretin receptors in non-neoplastic and neoplastic thyroid C-cells in rodents and humans: relevance for incretin-based diabetes therapy. *Neuroendocrinology*, 94:291-301.
34. Miederer M, Molatore S, Marinoni I, Perren A, Spitzweg C, Reder S, Wester H-J, Buck AK, Schwaiger M, **Pellegata NS**. (2011) Functional Imaging of Pheochromocytoma with 68Ga-DOTATOC and 11C-HED in a Genetically Defined Rat Model of Multiple Endocrine Neoplasia. *Int J Mol Imaging*;175352.
35. Lee M, Theodoropoulou M, Graw J, Roncaroli F, Zatelli MC, **Pellegata NS**. (2011) Levels of p27 sensitize to dual PI3K/mTOR inhibition. *Mol Cancer Ther.* 10:1450-9.
36. Costa-Guda J, Marinoni I, Molatore S, **Pellegata NS**, Arnold A. (2011) Germline and Somatic Mutations of *CDKN1B* in Sporadic Parathyroid Adenomas. *J Clin Endocrinol Metab*, 96:E701-6.
37. Molatore S, Liyanarachchi S, Irmeler M, Perren A, Mannelli M, Ercolino T, Beuschlein F, Jarzab B, Wloch J, Ziaja J, Zoubaa S, Neff F, Beckers J, Höfler H, Atkinson MJ, **Pellegata NS**. (2010) MENX-associated pheochromocytoma shares gene expression patterns with human pheochromocytoma. *Proc Natl Acad Sci USA* 107:18493-8.
38. Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, degli Uberti EC, Zatelli MC, **Pellegata NS**. A novel germline p27 mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. *Hum Mutat*, 31:E1825-35.
39. Molatore S, Kiermaier E, Jung CB, Pulz E, Höfler H, Atkinson MJ and **Pellegata NS**. Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. (2010) *Mol Cancer*, 9:116.
40. Shyla A, Hölzlwimmer G, Calzada-Wack J, Bink K, Tischenko O, Guilly M-N, Chevillard S, Samson E, Graw J, Atkinson MJ and **Pellegata NS**. (2010) Allelic loss of chromosomes 8 and 19 in MENX-associated rat pheochromocytoma. *Int J Cancer*, 126:2362-72.
41. Noll S, Hampf G, Bausbacher H, **Pellegata NS**, Kranz H. (2009) Site-directed mutagenesis of multi-copy-number plasmids: Red/ET recombination and unique restriction site elimination. *BioTechniques*, 46: 527–533.
42. Henopp T, Anlauf M, Schmitt A, Schlenger R, Zalatnai A, Couvelard A, Ruzsniowski P, Schaps KP, Jonkers YM, Speel EJ, **Pellegata NS**, Heitz PU, Komminoth P, Perren A, Klöppel G. (2009) Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas. *J Clin Endocrinol Metab*, 94:213-217.
43. Bhardwaj A, Frankel WL, **Pellegata NS**, Wen P, Prasad ML. (2008) Versican expression in tumors - a tissue microarray-based study. *Appl Immunohistochem Mol Morphol*, 16:263-6.
44. **Pellegata NS**, Quintanilla-Martinez L, Keller G, Liyanarachchi S, Höfler H, Atkinson MJ, Fend F.

- (2007) Human pheochromocytomas show reduced p27Kip1 expression that is not associated with somatic gene mutation and rarely with deletions. *Virchows Archiv*, 451:37-46.
45. Yoon H, He H, Nagy R, Davuluri R, Suster S, Schoenberg D, **Pellegata N**, de la Chapelle A. (2007) Identification of a novel noncoding RNA gene, NAMA that is downregulated in papillary thyroid carcinoma with BRAF mutation, and associated with growth arrest. *Int J Cancer*, 15: 767-75.
  46. **Pellegata NS**, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ. (2006) Germline mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and man. *Proc Natl Acad Sci USA* 2006, 103:15558-63.
  47. Prasad ML, **Pellegata NS**, Huang Y, Nagaraja HN, Chapelle Ad A, Kloos RT. (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. *Mod Pathol* 18, 48-57.
  48. Aldred MA, Huang Y, Liyanarachchi S, **Pellegata NS**, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A, Eng C. (2004) Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. *J Clin Oncol*. 22, 3531-9.
  49. Prasad ML, Huang Y, **Pellegata NS**, de la Chapelle A, Kloos RT. (2004) Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. *Histopathology* 45, 39-46.
  50. Prasad ML, **Pellegata NS**, Kloos RT, Barbacioru C, Huang Y, de la Chapelle A. (2004) CITED1 protein expression suggests Papillary Thyroid Carcinoma in high throughput tissue microarray-based study. *Thyroid* 14, 169-75.
  51. Piotrowska K, **Pellegata NS**, Rosemann M, Fritz A, Graw J, Atkinson J. (2004) Mapping of a Novel MEN-like Syndrome Locus to Rat Chromosome 4. *Mammalian Genome* 15, 135-141.
  52. Huang Y., de la Chapelle A. and **Pellegata NS**. (2003) Hypermethylation, but not LOH, is associated with the low expression of *MT1G* and *CRABP1* in papillary thyroid carcinoma. *Int J Cancer* 104, 735-744.
  53. Yoon H, Liyanarachchi S, Wright FA, Davuluri R, Lockman JC, De La Chapelle A, **Pellegata NS**. (2002) Gene expression profiling of isogenic cells with different *TP53* gene dosage reveals numerous genes that are affected by *TP53* dosage and identifies *CSPG2* as a direct target of p53. *Proc. Natl. Acad. Sci. USA* 99, 15632-7.
  54. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, **Pellegata NS**, de la Chapelle A. (2001) Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. *Proc. Natl. Acad. Sci. USA* 98, 15044-9.
  55. Scovassi AI, **Pellegata NS**, Di Stefano L, Padovan L, Negri C, Prosperi E, Riva F, Ciomei M, Ranzani GN. (2001) Effects of Topoisomerase II inhibitors on gastric cancer cell lines characterized by different genetic lesions. *Anticancer Res.* 21, 2803-8.
  56. Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, **Pellegata NS**, Plattner R, Stanbridge EJ, Cajot JF. (2000) p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. *Int J Cancer* 288, 685-91.
  57. **Pellegata NS**, Dieguez-Lucena JL, Joensuu T, Lau S, Montgomery KT, Krahe R, Kivela T, Kucherlapati R, Forsius H and de la Chapelle A. (2000) Mutation in KERA, encoding keratocan, cause cornea plana. *Nature Genet.* 25, 91-95.
  58. Amadori D, Maltoni M, Volpi A, Nanni O, Scarpi E, Renault B, **Pellegata NS**, Gaudio M, Magni E, Vio A and Ranzani GN. (1997) Gene amplification and proliferative kinetics in relation to prognosis in gastric cancer. *Cancer* 79, 226-232.
  59. **Pellegata NS**, Antoniono RJ, Redpath JL, Stanbridge EJ. (1996) DNA damage and p53-mediated cell cycle arrest: a reevaluation. *Proc. Natl. Acad. Sci. USA* 93, 15209-15214.
  60. Campomenosi P, Ottaggio L, Moro F, Urbini S, Bogliolo M, Zunino A, Camoriano A, Inga A, Gentile SL, **Pellegata NS**, Bonassi S, Bruzzone E, Iannone R, Pisani R, Menichini P, Ranzani GN, Bonatti S, Abbondandolo A, Fronza G. (1996) Study on aneuploidy and p53 mutations in astrocytomas. *Cancer Genet. and Cytogenet.* 88, 95-102.

61. Chen WH, **Pellegata NS**, Wang PH. (1995) Coordinated effects of insulin-like growth factor I on inhibitory pathways of cell cycle progression in cultured cardiac muscle cells. *Endocrinology* 136, 5240-5243.
62. **Pellegata NS**, Cajot J-F, Stanbridge EJ. (1995) The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth. *Oncogene* 11, 337-349.
63. Tenti P, Romagnoli S, Silini E, **Pellegata NS**, Zappatore R, Spinillo A, Zara C, Ranzani GN, Carnevali L. (1995) Analysis and clinical implications of K-ras gene mutations and human papillomavirus infection in primary adenocarcinoma of the uterine cervix. *Int J Cancer* 64, 9-13.
64. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, **Pellegata NS**, Ranzani GN, Rickaert F, Kloppel G. (1994) Intraductal papillary-mucinous tumors represent a distinct group of pancreatic neoplasms: an investigation of tumor cell differentiation and K-ras, p53 and c-erbB2 abnormalities in 26 patients. *Virchows Archiv.* 425, 357-367.
65. Tenti P, Romagnoli S, **Pellegata NS**, Zappatore R, Giunta P, Ranzani GN and Carnevali L. (1994) Primary retroperitoneal mucinous cystadenocarcinomas: immunohistochemical and molecular study. *Virchows Archiv.* 424, 53-57.
66. Silini E, Bosi F, **Pellegata NS**, Romano AM, Volpato G, Romano A, Nazari S, Tinelli C, Ranzani GN, Solcia E, Fiocca R. (1994) K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma. *Virchows Archiv.* 424, 367-373.
67. **Pellegata NS**, Sessa F, Renault B, Bonato M, Leone BE, Solcia E and Ranzani GN. (1994) K-ras and P53 gene mutations in pancreatic cancer: ductal and non-ductal tumors progress through different genetic lesions. *Cancer Res.* 54, 1556-1560.
68. Ranzani GN, Renault B, **Pellegata NS**, Fattorini P, Magni E, Bacci F and Amadori D. (1993) Loss of heterozygosity and K-ras gene mutations in gastric cancer. *Hum. Genet.* 92, 244-249.
69. De Benedetti L, Varesco L, **Pellegata NS**, Losi L, Gismondi V, Casarino L, Sciallero S, Bonelli L, Biticchi R, Bafico A, Masetti E, James R, Heouaine A, Ranzani GN, Aste H, Ferrara G. (1993) Genetic events in sporadic colorectal adenomas: K-ras and p53 heterozygous mutations are not sufficient for malignant progression. *Anticancer Res.* 13, 667-670.
70. Renault B, Van den Broek M, Fodde R, Wijnen J, **Pellegata NS**, Amadori D, Khan MP, Ranzani GN. (1993) Base transitions are the most frequent genetic changes at P53 in gastric cancer. *Cancer Res.* 53, 2614-2617.
71. **Pellegata NS**, Losekoot M, Fodde R, Pugliese V, Saccomanno S, Renault B, Bernini LF, Ranzani GN. (1992) Detection of K-ras mutations in exocrine pancreatic cancer by denaturing gradient gel electrophoresis (DGGE). *Anticancer Res.* 12, 1731-1736.
72. **Pellegata NS**, Bergamaschi G, Amadori D, Aloia A, Ballarini P, Del Senno L, Amaducci L, Ranzani GN. (1991) A 5'-truncated c-myc gene variant not associated with a risk of cancer. *Hum. Genet.* 87, 579-582.
73. Ranzani GN, **Pellegata NS**, Previderè C, Saragoni A Vio A, Maltoni M, Amadori D. (1990) Heterogeneous proto-oncogenes amplification correlates with tumor progression and presence of metastases in gastric cancer patients. *Cancer Res.* 50, 7811-7814.

### **Reviews and book chapters**

1. Minaskan N and **Pellegata NS**. (2019) Multiple endocrine neoplasia-type 4 (MEN4) and other MEN1-like syndromes, in *Polyendocrine Disorders and Endocrine Neoplastic Syndromes*, Ed. A. Colao, M-L. Jaffrain-Rea, A. Beckers. Publisher: Springer Nature.
2. Mohr H and **Pellegata NS**. (2017) Animal models of MEN1. *Endocr Relat Cancer* 24:T161-T177.
3. **Pellegata NS** and Klöppel G. (2017) Multiple Endocrine Neoplasia Type 4 in *WHO Classification of Tumours of Endocrine Organs 4th Ed.*, Ed: Lloyd, Osamura, Klöppel, Rosai. Publisher: World Health Organization.

4. **Pellegata NS.** (2017) Tumor suppressor genes, in *Encyclopedia of Pathology*. Ed: van Krieken. Publisher: Springer International Publishing.
5. Wiedemann T and **Pellegata NS.** (2015) Animal models of multiple endocrine neoplasia. *Mol Cell Endocr*, S0303-7207:30013-7.
6. Lee M and **Pellegata NS.** (2013) Multiple endocrine neoplasia syndromes associated with mutation of p27. *J Endocrinol Invest*. 36:781-7.
7. Lee M and **Pellegata NS** (2013) MEN4, in *Genetic Endocrine Tumor Syndromes*, *Frontiers of Hormone Research*, Ed. C. Stratakis, 41:63-78.
8. **Pellegata NS** (2012) MENX. *Annales d'Endocrinologie*, 73:65-70.
9. **Pellegata NS** (2012) MENX and MEN4. *Clinics*, 67: Suppl 1:13-8.
10. Marinoni I and **Pellegata NS.** (2010) p27, a novel MEN gene? *Neuroendocrinology*, 93: 19-28.
11. Molatore S and **Pellegata NS** The MENX syndrome and p27: relationships with multiple endocrine neoplasia, in *Progress in Brain Research: Neuroendocrinology 2010*.
12. **Pellegata NS** and Ranzani GN. (1996) The significance of p53 mutations in human cancers. *Eur. J. Histochem.*, 40: 273-282.

**Scholar Metrics (source: Scopus October 2020): N.S. Pellegata: 4160 citations; h-index 31.**